Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[New aspects on giant cell tumor of bone].
Lüke J, Hasenfratz M, Möller P, Barth TFE. Lüke J, et al. Pathologe. 2018 Mar;39(2):125-131. doi: 10.1007/s00292-017-0391-9. Pathologe. 2018. PMID: 29110035 Review. German.
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers.
Monga S, Lehrich B, Delgado E, Yasaka T, Liu S, Cao C, Liu Y, Taheri M, Guan X, Koeppen H, Singh S, Liu JJ, Singh-Varma A, Krutsenko Y, Poddar M, Hitchens T, Foley L, Liang B, Rialdi A, Rai R, Patel P, Riley M, Bell A, Raeman R, Dadali T, Luke J, Guccione E, Ebrahimkhani M, Lujambio A, Chen X, Maier M, Wang Y, Broom W, Tao J. Monga S, et al. Among authors: luke j. Res Sq [Preprint]. 2024 Dec 12:rs.3.rs-5494074. doi: 10.21203/rs.3.rs-5494074/v1. Res Sq. 2024. PMID: 39711542 Free PMC article. Preprint.
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.
Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, Carlino MS, Pachynski RK, Cosman R, Chu QS, Damian S, Curigliano G, Tam R, Wang X, Jeyamohan C, Wang L, Zhu L, Santucci-Pereira J, Greenawalt DM, Tabernero J. Luke JJ, et al. Clin Cancer Res. 2024 Dec 13. doi: 10.1158/1078-0432.CCR-24-0439. Online ahead of print. Clin Cancer Res. 2024. PMID: 39670852
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.
Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, Deutsch JS, Das Neves RX, Rodrigues RR, McCulloch JA, Wang H, Hartman DJ, Badger JH, Fernandes MR, Bai Y, Sun J, Cole AM, Aggarwal P, Fang JR, Deitrick C, Bao R, Duvvuri U, Sridharan SS, Kim SW, A Choudry H, Holtzman MP, Pingpank JF, O'Toole JP, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg AM, Fury MG, Whiteaker JR, Zhao L, Paulovich AG, Najjar YG, Luke JJ, Kirkwood JM, Taube JM, Park HJ, Trinchieri G, Zarour HM. Davar D, et al. Among authors: luke jj. Cancer Cell. 2024 Nov 11;42(11):1898-1918.e12. doi: 10.1016/j.ccell.2024.10.007. Epub 2024 Oct 31. Cancer Cell. 2024. PMID: 39486411 Free article. Clinical Trial.
Development of an Objective Structured Assessment of Technical Skills for Sclerotherapy.
Ma MS, Zafar FS, Goldman MP, Munavalli GS, Zimmet SE, Nguyen TH, Mishra V, Cartee TV, Mann M, Hsu JTS, Silapunt S, Weiss RA, Weiss MA, Haq M, Ahmed A, Koza E, Shi VJ, Dave L, Yi M, Kang BY, Cahn B, Bae YSC, Kole LCS, Friedmann DP, Chow ML, Minkis K, Stücker M, Schlick CA, Hoss E, Hu JC, Kibbi N, Saikaly SK, Greywal T, Hooper D, Vashi NA, Boucher A, Ward KHM, Neuhaus IM, Ghareeb E, Luke J, Karen JK, Suggs A, Lucas J, Decker A, Brieva JC, Yoo SS, Suozzi K, Alam M. Ma MS, et al. Among authors: luke j. J Am Acad Dermatol. 2025 Jan;92(1):129-132. doi: 10.1016/j.jaad.2024.08.062. Epub 2024 Sep 15. J Am Acad Dermatol. 2025. PMID: 39288871 No abstract available.
528 results